FIGURE 1 from Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity
Year: 2023
Type: other
Abstract: Tumor tropism of TAA-specific T cells after localized intratumoral injection. A, A cartoon depiction of the treatment scheme for schedule (left) and positions of tumor implantation and T-cell injection (right). s.c.: subcutaneously; i.t.: intratumorally; i.c.: intacranially. B–D, Flow cytometry profiling of leukocytes from the indicated tissues from the treatment groups to show the distribution of pmel-1 T cells (Thy1.1+) in the subcutaneous tumors (B, left: representative flow cytometry dot plots; right: quantification of Thy1.1+ cells in the tumors), brain hemispheres (C) and peripheral lymphoid organs (D). The numbers in the upright corner of the dot plots indicate the frequency of Thy1.1+ cells (% of CD8+ leukocytes). Leukocytes were from grouped tissue (PBS: n = 3; pmel-1 T cells: n = 5) and processed in triplicate. The columns in the graphs represent the mean ± SD (n = 3). w/o tumor: without tumor; inguinal LN: inguinal lymph node; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Two-tailed Student t test.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4382240588